M&A
J&J in Talks to Buy Eye-Drug Maker Ollin for Up to $3.4 Billion
Johnson & Johnson is in advanced talks to buy Ollin Biosciences, a privately held developer of eye-disease drugs, for as much as $3.4 billion,…
Archive
Johnson & Johnson is in advanced talks to buy Ollin Biosciences, a privately held developer of eye-disease drugs, for as much as $3.4 billion,…